This is a single center, Phase I dose finding study of HCW9218 for the treatment of
advanced/metastatic solid tumor cancer (except pancreatic and primary brain cancers). HCW9218
is a novel bi-functional fusion protein complex administered by subcutaneous (SC) injection.
It is comprised of a soluble fusion of two human TGFβRII domains, human tissue factor, and
human IL-15, and a second soluble fusion of two human TGFβRII domains and a sushi domain of
human IL-15Rα. HCW9218 activates IL-15R signaling on effector immune cells and the dimeric
TGFβRII functions as a "trap" for all three human TGF-β isoforms.